Therapeutic Solutions International’s Subsidiary, Emvolio, Inc., Files Investigational New Drug Application for StemVacs Cancer Immunotherapy

OCEANSIDE, CA–(Marketwired – April 12, 2017) – Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of an Investigational New Drug (IND) application by its majority owned subsidiary, Emvolio, Inc., for use of its StemVacs cancer immunotherapeutic in patients with solid tumors. The trial seeks to establish safety and immune response of the cancer, targeting a new personalized dendritic cell vaccine.

“Completion of preclinical studies and submission to the FDA to initiate clinical trials is a major milestone for Emvolio. We are excited about the prospects of eventually adding this new weapon in the fight against cancer to the armamentarium available to oncologists,” said Timothy Dixon, Chairman of Emvolio. “The fact that StemVacs utilizes cells derived from the patient being treated, we believe this will provide a personalized element to this immunotherapy, which we anticipate will increase the possibility of an effective outcome.”

StemVacs is generated using dendritic cell progenitors isolated from patients, which are activated by a proprietary process which has previously been demonstrated to endow dendritic cells with the ability to produce “natural cytokines”, which kill cancer cells.

“It is a pleasure to work with the team at Emvolio on clinical translation of this exciting immunotherapeutic approach to cancer,” said Boris Reznik, Chairman and CEO of Biorasi, Inc. “As a Contract Research Organization (CRO) that loves to assist promising companies operating in the area of the Cutting Edge of Medicine, we are pleased that our collaboration has culminated into this regulatory filing.”

Biorasi is a customer-focused Contract Research Organization (CRO) that optimizes the design and delivery of clinical trials for its sponsors. Pharmaceutical companies around the globe have come to depend on Biorasi to consistently deliver success in clinical-phase development programs. Biorasi’s expertise includes a wide range of molecule types, therapeutic areas, and regulatory pathways.

About Therapeutic Solutions International, Inc.
The Company’s corporate website is

About Emvolio, Inc.
The Company’s corporate website is Emvolio, Inc. is a Delaware corporation.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Contact Information
Therapeutic Solutions International, Inc.
[email protected]